Pharsight

Drugs that contain Ivabradine

1. Corlanor patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7361650 AMGEN INC γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
Feb, 2026

(1 year, 11 months from now)

US7361649 AMGEN INC β-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
Feb, 2026

(1 year, 11 months from now)

US7879842 AMGEN INC Beta-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
Feb, 2026

(1 year, 11 months from now)

US7867996 AMGEN INC γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
Dec, 2026

(2 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Apr 22, 2026
Pediatric Exclusivity (PED) Oct 22, 2026

Market Authorisation Date: 22 April, 2019

Treatment: A method for treating heart failure in a human using a crystalline form of ivabradine hydrochloride

Dosage: SOLUTION;ORAL

More Information on Dosage

CORLANOR family patents

Family Patents